A recurrent variant in two patients with EMP2-nEDD.
Yunran Peng, N. Cesarato, Tsenka Tomova-Simitchieva, Sisi Zhao, Huijun Wang, Regina C. Betz, Ulrike Blume‐Peytavi, Zhimiao Lin
2026.2.8British Journal of Dermatology
Paper details
- Journal
- British Journal of Dermatology
- Published
- 2026.2.8
- Citations
- 0
- Fields
- Medicine
tlooto Summary
Functional studies revealed that the recurrent de novo heterozygous variant in EMP2 exhibited significantly reduced localization at the plasma membrane, disrupting lipid raft integrity and triggering ligand-independent EGFR activation and internalization.
Abstract
We identify a recurrent de novo heterozygous variant (c.11T>C, p.Leu4Pro) in EMP2 as a cause of EMP2-nEDD in two sporadic patients. Functional studies revealed that the variant exhibited significantly reduced localization at the plasma membrane, disrupting lipid raft integrity and triggering ligand-independent EGFR activation and internalization. Consequently, treatment with the EGFR inhibitor erlotinib led to significant clinical improvement in one patient after one month.
Citation format
PENG, Yunran, et al. A recurrent variant in two patients with emp2-nedd. British Journal of Dermatology, 2026, 194(5): 974–976.